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1. Introduction 
Cardiac and skeletal muscle contraction is triggered by the arrival of an action potential 
that locally and transiently depolarizes the plasma membrane. The entire chain of 
molecular events that link the arrival of the action potential and muscle contraction is 
called excitation-contraction coupling. This chapter will focus on the way membrane 
depolarization is sensed and how it triggers a massive increase in the cytosolic Ca2+ 
concentration. Plasma membrane depolarization is detected by L-type voltage-gated 
calcium channels whose activation allows Ca2+ entry into muscle cells. Cardiac and 
skeletal muscle voltage-gated calcium channels differ by their Ca2+ permeability. While 
cardiac channels lead to an important and rapid Ca2+ influx, skeletal muscle channel 
activation allows a moderate and rather slow Ca2+ entry (Bean, 1989). In fact, the 
molecular identity of the pore-forming channel subunit differs in both tissues, cardiac 
fibers expressing the Cav1.2 isoform while skeletal muscles express the Cav1.1 isoform. 
Nevertheless, the overall subunit composition of both channels, illustrated in Figure 1, 
bears interesting similarities. 
The opening of these ion channels in response to plasma membrane depolarization results 
from a complex series of conformational changes occurring mainly in the pore-forming 
subunits. In these subunits, positively charged S4 segments act as voltage-sensing 
mechanical transducers by altering their position within the plasma membrane as a function 
of voltage value (Nakai, Adams, Imoto, & Beam, 1994). How movements of other structural 
elements are related to these S4 repositioning is still an open but particularly important 
question with regard to the excitation-contraction coupling process as we will see later. In 
both tissues, the activation of L-type voltage-gated calcium channels produces the opening 
of another calcium channel located in the membrane of the sarcoplasmic reticulum, the main 
intracellular Ca2+ store in muscles. This process leads to a transient and important increase 
in cytoplasmic Ca2+ concentration that is at the basis of muscle contraction. This particular 
ion channel presents several interesting features: i) it is sensitive to the plant alkaloid 
ryanodine (and is therefore named “ryanodine receptor”), ii) it is positioned in such a way 
that it faces the L-type channel in order to maximize activation efficiency, and iii) in both 
tissues, its activation and inactivation are controlled by cytoplasmic Ca2+ and Mg2+ 
concentrations (Figure 2).  
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Fig. 1. Schematic representation of an L-type voltage-dependent calcium channel. Cav┙ is 
the voltage-sensing and pore-forming subunit, whereas ┙2├, ┚ and ┛ are auxiliary subunits. 
Cav┙ is constituted of four homologous hydrophobic domains linked by cytoplasmic loops. 
The II-III loop, that links domains II and III, is the focus of this review. The ┚ subunits is the 
only protein that is fully cytoplasmic.  
 
Fig. 2. Cartoon describing the general process of excitation-contraction coupling, starting by 
membrane depolarization (1), L-type channel activation and transfer of conformational 
change to the ryanodine receptor (2), ryanodine receptor opening and sarcoplasmic 
reticulum Ca2+ release (3), and muscle contraction (4). 
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As for the L-type calcium channels, two different types of ryanodine receptors are 
respectively expressed in skeletal (type 1 ryanodine receptor) and cardiac (type 2 ryanodine 
receptors) muscles. These two types of ryanodine receptors differ in their sensitivity to 
cytoplasmic Ca2+ concentration. Type 1 ryanodine receptor appears to be more sensitive to 
inhibition by high cytosolic Ca2+ concentration than type 2 ryanodine receptors. In contrast, 
there does not seem to be major differences with regard to activation by cytosolic Ca2+ (Chu, 
Fill, Stefani, & Entman, 1993; Fruen, Bardy, Byrem, Strasburg, & Louis, 2000; Michalak, 
Dupraz, & Shoshan-Barmatz, 1988). In vivo, cardiac type 2 ryanodine receptor appears to be 
less repressed by L-type calcium channel than type 1 ryanodine receptors as witnessed by 
the far greater likelihood to observe spontaneous channel openings (spark events) (H. 
Cheng, Lederer, & Cannell, 1993; Wier & Balke, 1999). The differences in biophysical 
properties between skeletal and cardiac L-type calcium channels on one hand, and skeletal 
and cardiac ryanodine receptors on the other hand, led to differences in excitation-
contraction coupling mechanisms between these two tissue. In cardiac tissues, Ca2+ entering 
through activated L-type channels is sufficient to directly activate type 2 ryanodine 
receptors. This chain of events is called Ca2+-induced Ca2+-release. In this case, opening of 
the type 2 ryanodine receptor strictly depends on extracellular Ca2+ (Nabauer, Callewaert, 
Cleemann, & Morad, 1989). Indeed, the Ca2+ release process through type 2 ryanodine 
receptors is a U-shape function of voltage and follows the U-shape voltage-dependence of 
external Ca2+ entry. Moreover, blocking external Ca2+ entry precludes voltage-activated Ca2+ 
release through type 2 receptors. Type 1 ryanodine receptors in skeletal muscles differ from 
type 2 ryanodine receptors in their mode of activation. In spite of the capability of type 1 
ryanodine receptors to perform Ca2+-induced Ca2+-release, the amplitude of Ca2+ entry 
through activated skeletal L-type channels is too low and its kinetic too slow to trigger a 
cardiac type Ca2+-induced Ca2+-release mechanism. Indeed, in these cells, the Ca2+ release 
process is no longer U-shaped in response to voltage increase and strictly follows the 
sigmoidal voltage-dependence of activation of L-type channels. Ca2+ permeability through 
skeletal L-type channels plays therefore a negligible role in the skeletal type excitation-
contraction coupling. In skeletal muscles, the voltage-dependent trigger of type 1 ryanodine 
receptor activation is the changes in L-type channel conformation. This process has been 
termed voltage-induced Ca2+ release (Schneider & Chandler, 1973; Tanabe, Beam, Powell, & 
Numa, 1988). While it may seem comfortable for intellectual construction to oppose Ca2+-
induced Ca2+ release to voltage-induced Ca2+ release, one should keep in mind that such a 
drastic distinction between these two mechanisms also presents intrinsic restrictions. In 
skeletal muscles, the conformation transmission between L-type channel and type 1 
ryanodine receptor requires a physical interaction between these channel types. While 
conceptually, the process of Ca2+-induced Ca2+ release in cardiac tissues does not require a 
physical interaction between the two channels, it would be a mistake to eliminate the 
hypothesis that conformational changes in cardiac L-type channels can also be transmitted 
directly to type 2 ryanodine receptor. Conversely, while skeletal L-type conformational 
changes are essential to trigger Ca2+ release through type 1 ryanodine receptors in skeletal 
muscles, ruling out a contribution of Ca2+ (originating from internal sources) in the release 
of Ca2+ itself may also represent a shortcut attitude. In this review we will therefore not 
oppose the two modes of Ca2+-release but simply take into account that in cardiac tissues 
external Ca2+ is an important factor, while in skeletal muscle conformational changes in L-
type channels is a more important factor. We will assume that cardiac L-type channels 
might also be in interaction with the ryanodine type 2 receptor. The next paragraph will 
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describe what is known in terms of molecular interactions between L-type channels and 
ryanodine receptors, focusing mainly on the most important determinants for excitation-
contraction coupling. 
2. Molecular determinants of the interaction between L-type channels and 
ryanodine receptors 
2.1 Contribution of two separate domains of the II-III loop of Cav1.1 in voltage-induced 
Ca
2+
 release 
Because voltage-induced Ca2+ release clearly relies on a direct interaction between skeletal 
muscle L-type and type 1 ryanodine receptor, most of the researches have focused on the 
interaction between these two channels. In this context, the use of animal models has been 
decisive in identifying molecular determinants critical for the excitation-contraction 
coupling process. Three mice models have been widely used: i) the dysgenic mice mdg 
corresponding to a natural knockout of the pore-forming subunit of skeletal L-type 
channels (Tanabe et al., 1988), ii) the dyspedic mice, a knock-out of type 1 ryanodine 
receptor (Takeshima et al., 1995), and iii) the ┚-null mice, a knock-out of the ┚ auxiliary 
subunit of the skeletal L-type channel. All these gene knock-outs produce lethality at birth 
by defective respiratory muscle function implying that studies are done with primary 
myotubes isolated from late embryos.   
 
Fig. 3. Amino acid positions of skeletal muscle Cav1.1 Domains A and C. Amino acid 
sequences of these domains are compared to those of equivalent domains of the cardiac L-
type Cav1.2 channel. 
In a first series of precept experiments, mdg myotubes were used to express chimeras 
between the pore-forming Cav┙ subunits of skeletal and cardiac L-type channels in order 
to identify a skeletal muscle-specific L-type determinant responsible for voltage-induced 
Ca2+ release. This approach led to the identification of one particularly important 
determinant, the large cytoplasmic loop between the second and third hydrophobic 
domains (called II-III loop) of Cav1.1 (Nakai, Tanabe, Konno, Adams, & Beam, 1998) (see 
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Figure 3). According to structural predictions, this loop would be of 137 (Cav1.1) to 146 
(Cav1.2) amino acids long. Further, restriction of the skeletal L-type domain responsible 
for voltage-induced Ca2+ release through type 1 ryanodine receptors locates a sequence of 
36 amino acids, 62 amino acids downstream of the start of I-II loop sequence. This domain 
is called Domain C. While this region is undoubtedly important in Cav1.1, the sequence 
homology with the equivalent Domain C of Cav1.2 remains nevertheless quite high. The 
replacement of Ala739, Phe741, Pro742 and Asp744 of Cav1.1 by, respectively, Pro, Thr, Thr 
and Glu of Cav1.2 reduces voltage-induced Ca2+ release (Kugler, Grabner, Platzer, 
Striessnig, & Flucher, 2004; Kugler, Weiss, Flucher, & Grabner, 2004). 
While these studies clearly demonstrated that Domain C is critical for allowing voltage-
induced Ca2+-release by L-type channels, the exact mechanism whereby this domain 
contributes to the process has still not been resolved. There is no solid evidence for a direct 
interaction between Domain C and the ryanodine receptor, suggesting that its mode of action 
is indirect or that this interaction relies on a transient conformation of the Cav┙ subunit 
controlled by voltage. Following the identification of the II-III loop as an important 
determinant in voltage-induced Ca2+ release, synthetic peptides corresponding to fragments 
of this loop were screened for their ability to interact with purified ryanodine receptors and 
modify their gating activity. Curiously, this approach led to the identification of a ryanodine 
receptor-interacting domain of the II-III loop that is different of Domain C. This sequence has 
been termed Domain A and corresponds to the amino acid region Thr671 to Leu690 of Cav1.1 
(Figure 2). One particular feature of this domain is the presence of a stretch of basic residues 
(8 amino acids out of 20 are either Arg or Lys residues). Domain A of Cav1.2 bears sequence 
homology (10 residues are identical out of 20 and 3 have homology). In spite of this high 
sequence homology, cardiac domain A is considerably enriched in acidic residues suggesting 
that its function may have evolved differently than its skeletal muscle counterpart. Proof of 
functional differences between cardiac and skeletal domain A comes from the fact that 
skeletal domain A interacts with type 1 ryanodine receptor but not type 2 (O'Reilly et al., 
2002). Conversely, cardiac domain A does not interact with type 1 ryanodine receptor (el-
Hayek, Antoniu, Wang, Hamilton, & Ikemoto, 1995; O'Reilly et al., 2002). Curiously, there 
are no reports on the potential interaction between cardiac domain A and type 2 ryanodine 
receptor thereby illustrating the little credit the scientific community is giving to the 
possibility that cardiac L-type and type 2 ryanodine receptors physically interact. While 
direct interaction of skeletal domain A with type 1 ryanodine receptor, and evidence for 
functional effects (reviewed in paragraph 3), would ensure that this domain plays a critical 
role in excitation-contraction coupling, this possibility is hotly debated. In 2000, a study 
reported that the partial scrambling of skeletal domain A had little impact on excitation-
contraction coupling (Proenza, Wilkens, & Beam, 2000). Careful examination of the 
scrambled sequence reveals that scrambling occurs on the ten last residues of domain A and 
that many of the residues remain in fact at the same position. Moreover a characteristic 
feature of domain A, a rich content in basic amino acid, is conserved in the scrambled 
sequence. At the functional level, while excitation-contraction coupling is preserved in 
principle, no quantification of the extent of this conservation is performed. While these data 
are interesting, it would have been preferable to perform a more extensive scrambling of the 
sequence (using the entire domain and avoiding conservation of position for some residues). 
Other evidences question the role of domain A in excitation-contraction coupling. 
Replacement of the skeletal Cav1.1 II-III loop by the II-III loop of Musca domestica Cav┙ 
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channel, which has a poor homology with Cav1.1, largely prevents excitation-contraction 
coupling, but not completely, while reintegration of skeletal type domain C in this construct 
is enough to restore voltage-induced Ca2+-release (Wilkens, Kasielke, Flucher, Beam, & 
Grabner, 2001). It should be mentioned that the chimera construct in which the entire II-III 
loop is replaced displays very little Ca2+ permeability, possibly questioning the correct 
functioning of the chimera channel. The study lacks also a chimera construct with the 
integration of skeletal muscle domain A rather than domain C. Also, expression of two 
skeletal Cav1.1 hemi-channels, one lacking domain A, reconstitutes voltage-induced Ca2+ 
release in mdg myotubes (Ahern, Arikkath et al., 2001). Similarly, complete deletion of 
domain A in Cav1.1 does not affect the amplitude of voltage-induced Ca2+ release, although it 
seems to speed the process (Ahern, Bhattacharya, Mortenson, & Coronado, 2001). Very 
curiously, in the later study, the same authors demonstrate that deletion of both domains A 
and C results in the reappearance of some voltage-induced Ca2+ release. While these studies 
indicate that the presence of domain A is not strictly necessary to observe voltage-induced 
Ca2+ release in skeletal muscles, it is hard to conclude that it has no function at all. Also, 
while domain C appears to be important to observe the excitation-contraction coupling 
process, the data tend to indicate that there might be some interdependence between II-III 
loop domains to exert their function. Indeed, it was observed in vitro that domain C exerts an 
inhibitory effect on the activating function of domain A on Ca2+ release from type 1 
ryanodine receptor or on [3H]-ryanodine binding (el-Hayek, Antoniu et al., 1995; Ikemoto & 
el-Hayek, 1998).  
2.2 The skeletal muscle L-type channel contains other important determinants for 
excitation-contraction coupling 
While the II-III loop of Cav1.1 has focused much of the attention in the comprehension of the 
excitation-contraction coupling process, it is important to mention that other relevant L-type 
channel determinants have been proposed to play a role in the process. Two of these 
determinants are present on the Cav1.1 pore-forming subunit (the III-IV loop and the C-
terminal domain), and the second is constituted by the auxiliary ┚1a subunit. Their 
implication is summarized hereunder. 
Suspicion of the involvement of the III-IV loop of Cav1.1 arose as a consequence of the 
identification of a point mutation (Arg1086His) associated to malignant hyperthermia, a 
skeletal muscle pathology in which inhalation of volatile anesthetics provokes enhanced 
Ca2+ release from the sarcoplasmic reticulum, excessive ATP hydrolysis, heat production 
and therefore muscle damage (Monnier, Procaccio, Stieglitz, & Lunardi, 1997). A functional 
analysis of this mutation highlights a putative role of this loop in controlling the voltage-
dependence of the Ca2+ release thru type 1 ryanodine receptor and its caffeine sensitivity 
(Weiss et al., 2004). Caffeine is a well characterized exogenous activator of all types of 
ryanodine receptors favors Ca2+-induced Ca2+ release by sensitizing the ryanodine receptors 
to activating cytosolic Ca2+. A potential interaction site of this loop on type 1 ryanodine 
receptor has been identified that encompasses amino acids 922 to 1112 (Figure 4) (Leong & 
MacLennan, 1998b).  
It is noteworthy that this III-IV loop is extremely conserved among Cav┙ subunits (with 46 
amino acids identical on 53 between Cav1.1 and Cav1.2). This suggests that the cardiac III-IV 
loop may also interact with type 2 ryanodine receptor. 
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The C-terminus of Cav1.1 has also been shown to be an interesting determinant. The amino 
acid region 1543 to 1647 of Cav1.1 plays a role in the transport and targeting of Cav1.1 to the 
triad (Flucher, Kasielke, & Grabner, 2000; Proenza, Wilkens, Lorenzon, & Beam, 2000). The 
1393 to 1527 amino acid region of Cav1.1 binds Ca2+ and calmodulin. In the absence of 
calmodulin, this domain has been shown to bind type 1 ryanodine receptor at amino acid 
position 3609 to 3643. A synthetic peptide corresponding to the 1487 to 1506 region of Cav1.1 
inhibits both ryanodine binding and ryanodine receptor channel gating in bilayers (Sencer et 
al., 2001; Slavik et al., 1997). The authors of these findings suggest that these domains could 
participate to Ca2+ and/or calmodulin regulation of voltage-induced Ca2+ release, but more 
studies are warranted to confirm their importance. 
 
Fig. 4. Summary of known protein interactions between skeletal muscle L-type Cav1.1 and ┚ 
subunits with type 1 ryanodine receptor. The amino acid positions of Domains A and C are 
defined in the text. 
As mentioned above, absence of the ┚1a subunit of the L-type calcium channel led to a 
complete loss of excitation-contraction coupling in skeletal muscle. Recently, this subunit 
has been shown to directly interact with the type 1 ryanodine receptor (W. Cheng, Altafaj, 
Ronjat, & Coronado, 2005). Binding experiments identified a cluster of positively charged 
residues of type 1 ryanodine receptor that control this interaction. Neutralization or deletion 
of these amino acids severely depress the amplitude of the depolarization induced Ca2+ 
release through type 1 ryanodine receptor, indicating that this interaction is important in the 
regulation of the excitation-contraction coupling in skeletal muscles. 
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3. Is domain A of relevance to excitation-contraction coupling?  
Although the functional relevance of domain A is questioned by studies that have used chimera 
Cav┙ channels, we still believe that it is of interest to investigate the precise role of domain A in 
excitation-contraction coupling. Indeed, it is important to note the intrinsic limitations of 
several reports that rely on the use of chimera channels and mdg myotubes. For a chimera 
channel to integrate into the triad (the plasma membrane loci where skeletal muscle excitation-
contraction takes place), it needs to preserve sufficient molecular determinants that guarantee 
normal cell trafficking and correct localization with regard to type 1 ryanodine receptor. The 
role of these determinants on excitation-contraction coupling, and specifically on voltage-
induced Ca2+-release, cannot be investigated. Also, these studies and conclusions are all based 
on the assumption (that is not yet proven) that Ca2+-induced Ca2+-release by cardiac L-type 
channels and type 2 ryanodine receptors can occur in the absence of conformational changes in 
Cav1.2 (invariably triggered by voltage changes). Testing this hypothesis would require to 
block voltage-dependent Cav1.2 charge movements without blocking Ca2+ permeability. While 
this is a provocative opinion, one could conclude that the chimera studies have demonstrated 
that skeletal muscle domain C governs the requirement on external Ca2+ to produce Ca2+ 
release: when skeletal domain C is present, external Ca2+ would not be required, while when 
absent, external Ca2+ is mandatory. Domain C is undoubtedly important in participating to 
voltage-induced Ca2+ release. However, how is domain C voltage-dependent and how does it 
transmit voltage-dependent conformational changes to type 1 ryanodine receptor without 
directly interacting with this channel?  
In voltage-induced Ca2+-release, which occurs in skeletal muscles, the initial trigger for Ca2+ 
release through type 1 ryanodine receptor is brought by the voltage change. However, voltage 
might be considered as the initial trigger for initiating the Ca2+ release process, and the 
released Ca2+, once it has reached a critical concentration, may contribute to the process by 
promoting Ca2+-induced Ca2+ release. This can be expected to occur as type 1 ryanodine 
receptor is perfectly capable to support Ca2+-induced Ca2+ release instead of voltage-induced 
Ca2+ release such as when Cav1.2 replaces Cav1.1. While there is no doubt that type 1 
ryanodine receptor can support both voltage- and Ca2+-induced Ca2+ release, very little is 
known on the contribution of the different Cav1.1 domains (in particular A and C) to the balance 
between these two triggering processes. Among other arguments in favor of a contribution of 
domain A to excitation-contraction coupling is the fact that domain A is heavily charged. 
Obviously, voltage-induced Ca2+ release requires both the presence of Cav1.1 domain C in the 
context of an operational channel and a change in voltage, but it is expected that one type 1 
ryanodine receptor-interacting Cav1.1 determinant is altering its conformation upon 
depolarization to influence excitation-contraction coupling. The basic nature of domain A is of 
interest in that respect since (i) it binds type 1 ryanodine receptor, (ii) influences the Ca2+ 
sensitivity of type 1 ryanodine receptor, and (iii) is susceptible to sense voltage changes owing 
to its close proximity with the plasma membrane. This latter point has never been investigated 
of course, but needless to say, domain C is not the most convincing candidate as voltage-sensor 
owing to its location within the channel and the lower net charge of the sequence. Earlier 
evidences that domains A and C may interact are also interesting since it could be envisioned 
that voltage-changes alter the interaction between these two domains thereby dynamically 
regulating excitation-contraction coupling. Finally, most of the studies on excitation-
contraction coupling and on voltage-induced Ca2+ release in particular have focused their 
attention on the release process itself but not on the termination of the signal upon membrane 
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repolarisation. In that respect, it would be interesting to have a careful examination of the role 
of domain A on the ending of voltage-induced Ca2+ release.  
4. Animal toxins presenting an intriguing sequence homology with domain A 
In the course of ongoing studies on ryanodine receptor channel pharmacology, the group of 
Coronado identified imperatoxin A as an effector of type 1 ryanodine receptor (Valdivia, 
Kirby, Lederer, & Coronado, 1992). The toxin has high affinity for the channel (close to 10 
nM), produces an increase in channel opening probability by reducing the closure times, 
induces Ca2+ release from purified sarcoplasmic reticulum and increases [3H]-ryanodine 
binding by conversion of the ryanodine binding site from a low to a high affinity state (el-
Hayek, Lokuta, Arevalo, & Valdivia, 1995). Imperatoxin A was isolated from the venom of 
the African scorpion Pandinus imperator. It is a 33 amino acid peptide containing six cysteine 
residues and therefore three internal disulfide bridges. The pattern of connectivity results in 
a fold of the “inhibitor cysteine knot” type with three ┚-strands (Green et al., 2003). The 
peptide was first synthesized in 2007 (Zamudio et al., 1997). Since this initial discovery, 
other toxins have been identified, coming from the venom of other scorpions, that all share 
high sequence homology with imperatoxin A (Figure 5). These include maurocalcine in 2000 
from Scorpio maurus palmatus (Mosbah et al., 2000), immediately synthesized in 2000 (Fajloun 
et al., 2000), two opicalcine variants in 2003 (S. Zhu, Darbon, Dyason, Verdonck, & Tytgat, 
2003), hemicalcin in 2007 (Shahbazzadeh et al., 2007), and hadrucalcin in 2009 (Schwartz et 
al., 2009). All of these peptides have been tested on type 1 ryanodine receptor and shown to 
possess similar pharmacological properties as imperatoxin A. These toxins therefore define 
a family of functional homologous peptides. 
 
Fig. 5. Amino acid sequences and alignment of maurocalcine-like toxins acting on ryanodine 
receptors. Sequence homology with skeletal muscle domain A is also shown. Positively 
charged residues are shown in blue, sequence identities are given in red and the year of 
discovery of each toxin is also provided. 
A close comparison of the peptide sequences reveals an important conservation. All 
peptides are heavily charged, containing mostly Lys residues and some Arg residues, and 
Maurocalcine GDC1LPHLKLC2KENKDC3C4SKKC5KRRGTNIEKRC6R
Imperatoxin A GDC1LPHLKRC2KADNDC3C4GKKC5KRRGTNAEKRC6R
Opicalcine 1 GDC1LPHLKRC2KENNDC3C4SKKC5KRRGTNPEKRC6R
Opicalcine 2 GDC1LPHLKRC2KENNDC3C4SKKC5KRRGANPEKRC6R
Hemicalcin     GDC1LPHLKLC2KADKDC3C4SKKC5KRRGTNPEKRC6R
Hadrucalcin  SEKDC1IKHLQRC2RENKDC3C4SKKC5SRRGTNPEKRC6R
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the net charge of these peptides is high (+7 if one excludes the potential basic charge of the 
His residue that is present in all toxins). Most of these basic residues are located on one face 
of the molecule, creating an important dipole moment in these toxins (Boisseau et al., 2006). 
A closer examination of these sequences also reveals that a limited stretch of the primary 
structure of the toxins is highly homologous to the primary structure of skeletal muscle 
domain A (Figure 4). Moreover, modification of domain A, meant to further improve the 
structural similarity between domain A and imperatoxin A and maurocalcine, led to a 
mutant domain A with increased functional effects on type 1 ryanodine receptors (Green et 
al., 2003). These effects include stimulation of Ca2+ release from sarcoplasmic reticulum 
vesicles and increased channel opening probability of type 1 ryanodine receptor 
incorporated in lipid bilayers. Of note, following the action of this optimized domain A 
peptide, these toxins have no cumulative effect on channel activation, strongly suggesting 
that domain A and the toxins share the same binding site on the ryanodine receptors. These 
experiments highlight in any case the functional relevance of this limited structural 
homology between domain A and the toxins. Further evidence for the importance of this 
cluster of residues comes from an elegant study of the group of Valdivia. The cardiac domain 
A, which is poorly activator of type 1 ryanodine receptor, can be modified to become a 
strong type 1 ryanodine receptor activator by selected mutations within this cluster of 
residues (X. Zhu, Gurrola, Jiang, Walker, & Valdivia, 1999). The mutations were chosen in 
such a way that cardiac domain A integrates the cluster of basic residues of domain A that is 
homologous to the toxin sequences.  
5. In vitro functional similarities between maurocalcine and domain A 
Among the various toxin activators of ryanodine receptors, maurocalcine is one of the best 
characterized. Besides sequence similarities with domain A, and the emerging evidence that 
both skeletal muscle domain A and maurocalcine share the binding sites on type 1 ryanodine 
receptor, there is also cumulative indication for functional similarities. We rapidly 
summarize these similarities hereunder. First, both domain A and maurocalcine enhance 
channel activity by promoting an increase in channel opening probability and the 
appearance of a subconductance state (Chen et al., 2003; Fajloun et al., 2000; Lukacs et al., 
2008; O'Reilly et al., 2002). Both peptides differ however with regard to the level of 
subconductance state and the duration of channel opening in this subconductance state. 
Toxins promote long-lasting openings in the subconductance state that are barely observed 
with domain A. Interestingly, the various toxins also differ among each other with regard to 
the level of subconductance states (Chen et al., 2003; el-Hayek, Lokuta et al., 1995; Tripathy, 
Resch, Xu, Valdivia, & Meissner, 1998), suggesting that sequence divergences may control 
this subconductance level. Indeed, we observed that single point mutations in maurocalcine 
modify this subconductance level (Lukacs et al., 2008). The absence of long-lasting events 
with domain A might also reflect its significantly lower affinity for type 1 ryanodine receptor 
compared to the toxin. Second, in agreement with their potentiating effects on channel 
activity, both maurocalcine and domain A induce Ca2+ release from purified sarcoplasmic 
reticulum vesicles (Dulhunty et al., 1999; el-Hayek, Antoniu et al., 1995; Esteve et al., 2003). 
These stimulating effects of domain A on Ca2+ release are observed at high concentrations 
(above 10 µM in general) and are not consistently reported. In one study, application of 
peptide A was reported to decrease the caffeine- and Ca2+-induced Ca2+ release (Chen et al., 
2003), indicating in any case a relationship between the binding site of domain A and the 
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Ca2+-sensitivity of the type 1 ryanodine receptors. In the same study, high concentrations of 
peptide A actually block the effect of maurocalcine, again suggesting that both peptides 
bind onto the same site on the type 1 ryanodine receptor. The variable response of type 1 
ryanodine receptor to domain A, as can be concluded from the various reports, also suggest 
that peptide conformation or cofactors largely influence the response of type 1 ryanodine 
receptor to domain A. Third, both domain A and maurocalcine increase [3H]-ryanodine 
binding (Chen et al., 2003; el-Hayek, Antoniu et al., 1995; Gurrola et al., 1999; Lu, Xu, & 
Meissner, 1994; X. Zhu et al., 1999). This stimulation is expected since conditions that trigger 
ryanodine channel opening are reported to produce a conversion in the binding site for 
ryanodine from a low affinity state to a higher one. The amplitude of the increase in [3H]-
ryanodine binding, triggered by domain A, maurocalcine or other toxins, appears quite 
variable. This stimulation depends on other factor, such as the concentrations of cytosolic 
Ca2+ (Esteve et al., 2003; Tripathy et al., 1998) and Mg2+ (unpublished observations). This 
dependence on cytosolic Ca2+ concentration deserves some important comments that may 
be of interest for the understanding of excitation-contraction coupling. Cytosolic Ca2+ 
concentration has a biphasic effect of [3H]-ryanodine binding and channel gating, being an 
activator at low concentrations (above 100 nM) and inhibitor at higher concentrations 
(between 10 µM and 1 mM). Interestingly, maurocalcine and imperatoxin A were reported 
to alter this Ca2+-dependence by sensitizing type 1 ryanodine receptors to both the 
stimulation and inhibitory effects of Ca2+ (Esteve et al., 2003; Tripathy et al., 1998). For 
instance, while 100 nM Ca2+ does not trigger Ca2+ release from type 1 ryanodine receptor, 
this same concentration will produce Ca2+-induced Ca2+-release in the presence of 
maurocalcine. This is an important observation because it means that binding of 
maurocalcine on type 1 ryanodine receptor makes it prone to perform Ca2+-induced Ca2+ 
release. The analogy between maurocalcine and peptide A questions the possibility that 
domain A controls the ability of type 1 ryanodine receptors to perform Ca2+-induced Ca2+ 
release. The possibility that this control is revealed during membrane depolarization opens 
interesting questions.  
An important finding has been the identification of peptide A and toxin binding site on 
type 1 ryanodine receptors. A first report describes the location of biotinylated 
imperatoxin A binding sites on tetramers of type 1 ryanodine receptors (Samso, Trujillo, 
Gurrola, Valdivia, & Wagenknecht, 1999). This study illustrates that four imperatoxin A 
can bind onto a cytoplasmic domain of the tetramer of type 1 ryanodine receptors 
between the clam and handle domains, 11 nm away from the transmembrane pore.  The 
far distance of binding of imperatoxin A indicates that its effect on channel gating occurs 
through an allosteric mechanism. In a 3D reconstruction of type 1 ryanodine receptor, the 
imperatoxin A binding site is in close physical proximity to the Ca2+-calmodulin binding 
site (Wagenknecht & Samso, 2002). More precise location of the binding sites of the toxins 
has been investigated using recombinant fusion protein of fragments of the type 1 
ryanodine receptor. Using biotinylated maurocalcine and peptide A, Altafaj and coll. 
identified two type 1 ryanodine receptor sequences that bind either domain A or 
maurocalcine (Altafaj et al., 2005). Weak interaction was observed with a fragment 
encompassing amino acid region 1021 to 1631 that contains the 37 amino acid sequence 
that was previously shown to bind to the skeletal muscle Cav1.1 II-III loop (Leong & 
MacLennan, 1998a). Stronger interaction was shown to occur with amino acid region 3351 
to 3507. These findings are in agreement with the predicted localization of imperatoxin A 
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binding site on the 3D structure of type 1 ryanodine receptor. They are also in agreement 
with the suggestion that these two regions are in close proximity in space, thereby 
suggesting that they constitute a single binding site. In any case, these data demonstrate 
for the first time that maurocalcine and domain A share the same binding site. Of 
importance, it has been observed that deletion of the 1272-1455 amino acid region within 
type 1 ryanodine receptor provokes the loss of depolarization induced Ca2+ release (Perez, 
Mukherjee, & Allen, 2003). Combined these observations reinforce the idea that domain A 
and its binding site are somehow involved in the control of voltage-induced Ca2+ release. 
While maurocalcine has limited functional effects on type 2 ryanodine receptors, it is 
interesting to note that it binds to this receptor through an homologous binding site 
(regions 1033 to 1622 and 3558 to 3609 of type 2 ryanodine receptors) (Altafaj et al., 2007). 
These results suggest that binding of the toxin can be dissociated from its functional 
effect. This possibility has lately been reinforced by unpublished observations showing 
that the effect of maurocalcine depends on the redox state of type 1 ryanodine receptor. 
Differences in redox states between type 1 and 2 ryanodine receptors may thus explain 
differences in maurocalcine effects on these two channels. Of note, the redox state of type 
2 ryanodine receptor has been shown to control its activity under cardiomyocytes stretch 
conditions (Prosser, Ward, & Lederer, 2011). 
6. Use of maurocalcine to understand excitation-contraction coupling in 
skeletal muscle cells 
During the course of maurocalcine characterization, we have shown that external 
application of maurocalcine on cultured skeletal muscle myotubes produces a small, but 
detectable, transient cytoplasmic Ca2+ elevation (Esteve et al., 2003). This effect is also 
observed in the absence of external Ca2+ demonstrating the mobilization of intracellular 
stores. Finally, maurocalcine interferes with the action of 4-chloro-m-cresol indicating the 
involvement of type 1 ryanodine receptors. This was the first demonstration of a 
pharmacological effect of a maurocalcine-type toxin on intact muscle cells. Since then, 
similar observations have been made with imperatoxin A and hadrucalcin on cardiomycytes 
(Gurrola, Capes, Zamudio, Possani, & Valdivia, 2010; Schwartz et al., 2009). These 
observations have prompted us to investigate the cell penetration properties of 
maurocalcine. A series of studies have demonstrated since 2005 that maurocalcine belongs 
to the cell penetrating peptide family with vector properties that can be derived for various 
diagnostic, imaging and therapeutic applications (Aroui et al., 2009; Boisseau et al., 2006; 
Esteve et al., 2005; Jayagopal et al., 2009; Mabrouk et al., 2007; Poillot et al., 2010). A more 
detailed investigation of the mode of action of maurocalcine in developing skeletal muscle 
cells and adult fibers reveals that the peptide acts preferentially on type 1 ryanodine 
receptors that are uncoupled from the L-type calcium channels (Szappanos et al., 2005). 
Indeed, maurocalcine increases the frequency of spontaneous Ca2+ release events followed 
by the appearance of ember-like long lasting Ca2+ release events in permeabilized adult 
muscle fibers. Muscle permeabilization is expected to favor the uncoupling between type 1 
ryanodine receptors and L-type calcium channels. These observations tend to indicate that 
maurocalcine has difficulties to act on type 1 ryanodine receptors when domain A of L-type 
channels already occupies the binding site on type 1 ryanodine receptor. Besides this effect 
of maurocalcine on uncoupled type 1 ryanodine receptors, the effect of the peptide was also 
investigated on L-type coupled type 1 ryanodine receptors by using high concentrations of 
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the peptide to gain accessibility to its binding site on the ryanodine receptor. Maurocalcine 
was injected into adult skeletal muscle fibers and Ca2+ transients induced by membrane 
depolarization. In these experiments, incubation with maurocalcine does not induce per se a 
change in resting cytoplasmic Ca2+ concentrations or amplitude of the depolarization-
induced Ca2+ release. Only minor effects of maurocalcine were observed on the onset 
kinetics and voltage-dependence of voltage-induced Ca2+ release. Although these effects are 
small, they tend to indicate that maurocalcine is able to occupy its binding site during 
depolarization. Interestingly, much stronger effects of maurocalcine were observed on the 
kinetics of the termination of Ca2+ release upon ending membrane depolarization (Pouvreau 
et al., 2006). These effects correlate with the duration and amplitude of membrane 
depolarization and confirm that depolarization progressively permits maurocalcine binding 
onto L-type coupled ryanodine receptors. Taken together, these experiments would suggest 
that domain A acts as a negative clamp on type 1 ryanodine receptor for Ca2+ release at 
resting membrane potential. In this configuration, its affinity for domain A is too high or the 
accessibility too restricted to allow maurocalcine binding to type 1 ryanodine receptor. 
Depolarization produces a change in conformation of domain A that reduces its affinity for 
the ryanodine receptor, thereby relieving the negative clamp for Ca2+ release. In this 
situation, maurocalcine gains access to the ryanodine receptor by competing with domain A 
for its binding site. Since maurocalcine does not trigger a gain of function with regard to 
Ca2+ release under membrane depolarization, this observation suggest that i) maurocalcine 
and domain A are functionally equivalent under depolarization, and ii) since maurocalcine is 
an activator of Ca2+ release, it is likely that domain A acquires activating functions under 
membrane depolarization. Upon membrane repolarization, domain A regains access to its 
binding site on the ryanodine receptor by increased affinity and competitive displacement of 
maurocalcine. The slow kinetics of maurocalcine displacement by domain A explains the 
slower termination of Ca2+ release. This sequence of events is depicted in Figure 6. 
In the scheme of events presented in Figure 6, domain A acts as a functionally versatile 
ligand: a negative clamp under resting membrane potential and an activator under 
membrane depolarization. By analogy with maurocalcine action, we hypothesize that the 
activating function of domain A stems from an increase in sensitivity of type 1 ryanodine 
receptor to cytoplasmic Ca2+. Two types of changes in Ca2+ sensitivity have been observed 
with maurocalcine: i) a shift in Ca2+ concentration required to activate Ca2+-induced Ca2+-
release towards lowers concentrations (from a threshold of 100 to 10 nm Ca2+), and ii) an 
enhanced amplitude of Ca2+-induced Ca2+ release. With such a mechanism in hand, the 
initial trigger of Ca2+ elevation that sparks Ca2+-induced Ca2+ release under these activating 
functions of domain A can be domain C. The Ca2+ sensitizing function of domain A under 
membrane depolarization highlights a new concept for excitation-contraction in skeletal 
muscles. Rather than opposing voltage-induced Ca2+ release and Ca2+-induced Ca2+ release, 
the two phenomena might be closely linked. Voltage-induced Ca2+ release could be termed 
voltage-induced Ca2+-induced Ca2+ release. The Ca2+ responsible for the induction of Ca2+-
induced Ca2+ release would originate from the initial opening of type 1 ryanodine receptor. 
In skeletal muscles, the presence of a negative clamp might be required to avoid 
spontaneous Ca2+ release events that otherwise would spark on Ca2+ release and 
contraction. In this scheme, the absence of domain A mainly alters the Ca2+ sensitivity of type 
1 ryanodine receptors and does not prevent any activating function of domain C. When 
domain A is modified, change in Ca2+ dependence should be observed. However, this is 
www.intechopen.com
 
Chemical Biology 378 
extremely difficult to address in classical experimental conditions where cytosolic Ca2+ 
concentration is not under control. 
 
Fig. 6. Putative model of type 1 ryanodine receptor activation in skeletal muscles and role of 
domain A. A: domain A; C: domain C; ?: unknown putative domain C protein partner or receptor 
binding site. Membrane depolarization triggers domain C-mediated ryanodine receptor 
opening, while activating the Ca2+-sensitizing function of domain  A. Ca2+-induced Ca2+-release 
becomes the major sources of cytosolic Ca2+ elevation. Domain A interaction with the 
ryanodine receptor is weakened and maurocalcine can replace domain A with equivalent 
function. Upon membrane repolarization, the activating function of domain C is lost, domain A 
regains its affinity and the Ca2+ sensitivity is lost. If maurocalcine was occupying domain A 
binding site on the receptor, it is slowly displaced by the inhibitory conformation of domain A 
explaining the continuing Ca2+ release process in the interval, assuming that the activating 
function of maurocalcine is voltage-independent or at least less voltage-sensitive. 
7. Conclusion 
One common feature between domain A and maurocalcine is that both are positively 
charged. Interestingly, maurocalcine has been shown to possess a strong affinity for 
negatively charged membrane lipids (Boisseau et al., 2006; Ram et al., 2008), namely 
phosphatidylserine and phosphoinositides, but also gangliosides. Also, cell penetration of 
maurocalcine presents a voltage-sensitive component (Boisseau et al., 2006). These properties 
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introduce three interesting questions. First, does domain A interact with the plasma membrane, 
and in particular with negatively charged lipids? Second, owing to its close proximity with the 
plasma membrane and its charged nature, does domain A sense changes in membrane 
potential? Third, if yes, does domain A possess some of the plasma membrane translocation 
properties of maurocalcine by physically invading the plasma membrane during 
depolarization? While these questions remain unanswered, they may be of interest because 
these considerations could impact the possible voltage-dependent relationship existing 
between domain A and type 1 ryanodine receptor. Owing to its privileged interaction with type 
1 ryanodine receptor through a discrete binding site, domain A may also confer voltage-
sensitivity to the ryanodine receptor. Maurocalcine, as a tool, clearly demonstrated that the 
domain of type 1 ryanodine receptor on which maurocalcine or skeletal domain A binds plays 
an important role in the control of channel opening through pore-distant allosteric 
modifications. Therefore, it is conceivable that depolarization-induced movement of domain A 
within this site could impact the allosteric change that control type 1 ryanodine channel 
opening. Of note, while skeletal muscle domain A has a net positive charge of +6, cardiac 
domain A has a net charge of 0 making it far less suitable to sense changes in membrane 
potential. By extension, these considerations of voltage-dependence could apply to other 
domains of the II-III loop of voltage-gated calcium channels. One striking feature of domain C 
is that, contrary to domain A, it is negatively charged (12 residues out of 36 are negatively 
charged in skeletal and cardiac domain C – net negative charge -9). On the basis of these 
observations, one can therefore question the existence of a voltage-sensitivity in the 
conformation of domain C. Also, taking over an idea that has been postulated in the past, it 
wouldn’t be unlikely, considering the electrostatic complementarities of domains A and C, that 
both domains interact with each other and that this interaction is under the control of voltage 
changes. This questions the specific relationship that might exist between domain A and domain 
C for the control of voltage-induced Ca2+ release.  
Most studies that have been performed up to now in order to understand the roles of 
channel cytoplasmic domains in excitation-contraction coupling have suffered from a lack of 
structural knowledge. The identification of a restricted binding site of maurocalcine and 
domain A on ryanodine receptors opens the door to a better definition of the critical 
interacting amino acid residues through RMN studies. These structural studies are currently 
underway and indicate that some specific type 1 ryanodine receptor amino acids are 
involved in the interaction with both domain A and maurocalcine (unpublished results). At 
last, the identification of the essential amino acids will allow refined functional studies 
based on more precise Cav1.1 or ryanodine receptor channel mutagenesis. In the process of 
comparing the functional homologies between domain A and maurocalcine, it would be of 
interest to substitute domain A by maurocalcine sequence in Cav1.1. 
The importance of maurocalcine as a tool to investigate excitation-contraction coupling is 
demonstrated by the fact that, for the first time, this peptide allows a perturbation of the 
excitation-contraction coupling process in native cells without requiring the modification of 
any of the proteins involved, by mutagenesis or chimeras. Swapping domains between 
various ion channel isoforms is indeed a particularly tricky approach considering that there 
must be a delicate voltage-dependent conformational relationship between numerous 
important structural determinants. The use of maurocalcine has highlighted two important 
matters in the study of excitation-contraction coupling. First, it illustrates that the nature of 
the relationship between domain A and type 1 ryanodine receptor changes during membrane 
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depolarization. Second, it uncovers the unexpected importance of domain A in the 
termination of Ca2+ release during membrane repolarization. The precise description of this 
voltage-induced type 1 ryanodine closure is lacking so far. Nevertheless, this result is the 
first evidence for the role of Cav1.1 domain A in this silencing process. The importance of this 
step in the control of Ca2+ homeostasis and contraction would justify that more studies be 
devoted to this issue. 
The properties of maurocalcine to cross the plasma membrane suggest that it would be an 
interesting tool to modify excitation-contraction coupling in skeletal muscle in vivo. The fact 
that maurocalcine shares the same binding site than domain A on type 1 ryanodine receptor 
restricts its accessibility to L-type coupled ryanodine receptors. Obviously, it would thus be 
very interesting to investigate its effect on ryanodine receptors under conditions where its 
accessibility to the channel is not restricted, i.e. in the absence of Cav1.1. Effects of 
maurocalcine on mdg myotubes, lacking Cav1.1, are currently under investigation in our 
research team. These studies will provide important information on the effects of 
maurocalcine, and by inference on domain A, in a cellular context independent of the 
voltage-dependent channel environment and therefore also of the contribution of domain C.  
The evidence for a voltage-modulated contribution of domain A to excitation-contraction 
coupling prompted us to emphasize the limits existing in the opposition between voltage-
induced and Ca2+-induced Ca2+ release mechanisms. Investigations focused on Ca2+-induced 
Ca2+ release tend to take into account only the cell entry of Ca2+ from the extracellular space 
as trigger for Ca2+ release. The possible contribution of cytoplasmic or sarcoplasmic Ca2+ 
calcium in this process is not taken into account because of technical limitations. Indeed, it is 
quite difficult to maintain cytoplasmic Ca2+ at a certain concentration while at the same time 
measuring Ca2+ release from sarcoplasmic reticulum. Conversely, the possibility that type 2 
ryanodine receptor Ca2+ release undergoes voltage-dependence might be masked by the 
voltage-dependence of external Ca2+ entry. If one takes into account these limitations, it is 
possible to draw a number of working hypotheses that do not necessarily oppose cardiac 
and skeletal muscle excitation-contraction coupling. Indeed, in light of the maurocalcine 
effects, we propose that the voltage-dependent modification of type 1 ryanodine receptor by 
domain A induces an increase of its sensitivity to cytoplasmic Ca2+. Therefore, we propose to 
introduce the concept of voltage-induced-Ca2+ induced-Ca2+ release by which depolarization 
concomitantly promotes a change in Ca2+ sensitivity, through domain A of Cav1.1, and the 
opening, through domain C, of type 1 ryanodine receptor. In this model, the difference 
between cardiac and skeletal muscle excitation contraction coupling mechanism only resides 
on the absence of this change of Ca2+ sensitivity of the type 2  ryanodine receptor due to the 
absence of interaction of cardiac domain A with type 2 ryanodine receptor. 
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